About the Study

For adults with Bipolar Type 1 experiencing a current manic episode.

The goal of this study is to evaluate the efficacy, safety, and tolerability of BHV-7000, compared to placebo.
This study is sponsored by Biohaven Pharmaceuticals.

Length of Study:  2 weeks screening period. 3 weeks double-blind inpatient treatment period. 2 weeks  safety follow-up period.
Total length: Approximately 7 weeks.

Eligibility 

You may be eligible to participate in this study if you:

• are between the ages of 18-75 years old
• meet DSM-5 criteria for Bipolar Disorder Type 1 diagnosis
• are currently experiencing a recent onset manic episode
• are willing to stay in our 24-hour observation unit for 3 to 5 weeks.

If chosen for this study, you will be compensated for every study visit that you complete, and we can provide transportation if needed. 

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.